New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma

Scientists say slight inherited differences in the genes may help predict how mesothelioma patients will respond to chemotherapy.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Polymorphisms Impact Pemetrexed Chemotherapy

Genetic Variables and Mesothelioma Chemotherapy

These polymorphisms could serve as potential markers of pemetrexed treatment outcome in patients with malignant pleural mesothelioma.

Raleigh, NC (PRWEB) July 11, 2014

Cancer researchers in Slovenia say genetic variations called polymorphisms appear to have a significant impact on how patients respond to treatment with pemetrexed (Alimta), the most popular chemotherapy drug for mesothelioma. Surviving Mesothelioma has the full story. Click here to read the new post now.

Researchers at the University of Ljubljana and the Ljubljana Institute of Oncology tested mesothelioma patients on pemetrexed for different types of polymorphisms. They found that patients with genetic variations in the folate pathway or on certain transporter genes responded differently to pemetrexed than patients without these variations.

According to lead researcher Katja Goricar, a pharmacogeneticist with the Institute of Biochemistry at the University of Ljubljana, “These polymorphisms could serve as potential markers of pemetrexed treatment outcome in patients with malignant pleural mesothelioma.”

The study in Radiology and Oncology linked polymorphisms to longer or shorter survival, as well as liver and gastrointestinal toxicities.

“Without biomarkers for guidance, chemotherapy can be very ‘hit or miss’ in terms of its effectiveness,” says Surviving Mesothelioma Managing Editor Alex Strauss. “This research is encouraging news that mesothelioma treatment will continue to become more targeted and more effective.”

For a better understanding of how genetic differences may effect drug response, see Genetic Variables Impact Mesothelioma Chemotherapy Response, available now on the Surviving Mesothelioma website.

Goricar, K, et al, “Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma”, April 25, 2014, Radiology and Oncology, pp. 163-172, http://www.ncbi.nlm.nih.gov/pubmed/24991206

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.


Contact

Follow us on: Contact's Google Plus